Catalent (NYSE:CTLT) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a report released on Monday morning.

Several other analysts have also recently commented on the stock. Robert W. Baird reissued a “neutral” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Price Performance

NYSE:CTLT opened at $61.45 on Monday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.15 billion, a PE ratio of -27.19, a price-to-earnings-growth ratio of 2.43 and a beta of 1.16. Catalent has a 12 month low of $36.74 and a 12 month high of $61.50. The company’s 50-day moving average price is $59.93 and its two-hundred day moving average price is $58.55.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Catalent will post 0.84 EPS for the current fiscal year.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 in the last three months. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Several institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group acquired a new position in Catalent during the 3rd quarter worth approximately $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the second quarter valued at $42,000. Sentry Investment Management LLC acquired a new stake in Catalent in the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.